Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Stopped Study was terminated with the IRB ended early as logistical concerns of the SBRT
Conditions
- Borderline Resectable Pancreatic Cancer
Interventions
- DRUG: gemcitabine/nab-paclitaxel
- DRUG: mFOLFIRINOX
Sponsor
Nathan Bahary, MD